Brief: Xvivo Perfusion Q1 EBITDA Up At SEK 7.6 Mln
April 9 (Reuters) - Xvivo Perfusion AB XVIVO.ST :
* STRONG CASH FLOW DESPITE THE INFLUENCE OF COVID-19
* TOTAL NET SALES (INCL. DURABLE GOODS) IN QUARTER AMOUNTED
TO SEK
46.5 (47.7) MILLION
* Q1 OPERATING INCOME BEFORE DEPRECIATION AND AMORTIZATION
(EBITDA) AMOUNTED TO SEK 7.6 MILLION (3.2)
Source text for Eikon: ID:nWkr2yHDSL
Further company coverage: XVIVO.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))
Recent news on Xvivo Perfusion AB
See all newsSweden's XVIVO Q3 revenue beat expectations on thoracic sales
Brief: Xvivo Q3 EBIT SEK 28 Million
Brief: Xvivo Receives CE Certificates For Heart Preservation Technology
Brief: XVIVO Gets FDA Approval For Additional Patient Enrollment
Sweden's XVIVO Q2 sales beat estimates, helped by thoracic segment strength